Qdenga Dengue Vaccine Approved in India: A Step Forward, Not a Cure-All
India's first dengue vaccine, TAK-003 (Qdenga) by Takeda, has received clearance for use among individuals aged 4 to 60 years, marking a significant milestone in the fight against dengue. Evaluated in global trials and approved in over 40 countries, Qdenga offers strong protection against severe dengue and hospitalization without requiring pre-vaccination screening. However, it's not a silver bullet; its effectiveness against DENV-3 and DENV-4 serotypes is lower, which is concerning given India's evolving epidemiology. The vaccine modifies disease severity rather than blocking transmission, meaning outbreaks will persist. Cost and access remain challenges, with an indigenous candidate, 'DengiAll' by Panacea Biotec, in phase III trials, potentially offering broader protection and a single-dose regimen by 2027.
Key Points
- India's first dengue vaccine, TAK-003 (Qdenga) by Takeda, has been cleared for use in individuals aged 4-60 years.
- The vaccine provides strong protection against severe dengue and hospitalization and does not require pre-vaccination screening.
- Qdenga is more effective against DENV-1 and DENV-2 but less so against DENV-3 and DENV-4, which is a concern given India's evolving dengue epidemiology.
- The vaccine primarily modifies disease severity rather than blocking transmission, implying dengue outbreaks will continue.
- Cost and access are significant challenges, but an indigenous vaccine candidate, 'DengiAll' by Panacea Biotec, is in phase III trials, potentially offering broader protection by 2027.
Exam Facts
- India's first dengue vaccine is TAK-003, marketed as 'Qdenga', developed by Takeda.
- It received clearance from the Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI).
- The vaccine is approved for individuals aged 4 to 60 years.
- Dengue is caused by four serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
- An indigenous candidate, 'DengiAll', developed by Panacea Biotec in collaboration with ICMR, is in phase III clinical trials.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.